Circassia Establishes Commercial-Scale Supply Chain
Circassia to Develop Dopexamine as Part of Proprietary Post-Surgery
OXFORD, England, October 8 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, announced today that it has acquired the US, Canadian and Japanese development and commercialization rights to dopexamine from the international speciality pharmaceutical company Ipsen. Circassia has also entered into agreements with pharmaceutical manufacturers Excella and Hospira to establish a commercial-scale supply chain for the product.
Circassia is developing dopexamine in a new indication as an integral part of proprietary structured protocols designed to dramatically improve patient recovery following a range of high-risk surgeries. This novel approach, named ToleroCare(R), which Circassia has recently patented, combines the use of dopexamine with the administration of intra-venous fluids to improve tissue oxygenation levels during the recovery period after surgery. The precise use of fluids and dopexamine is based on carefully defined parameters such as heart stroke volume and oxygen delivery index.
ToleroCare therapy has already achieved clinical proof-of-concept in a phase II single-blind, randomized, controlled trial in 122 high-risk general surgery patients in the UK. The study showed that significantly fewer patients who received ToleroCare experienced complications in the 30 day period following surgery compared with those on standard treatment (44% vs. 68%; p = 0.003). In addition, ToleroCare patients recovered significantly quicker, staying in hospital for 17.5 days on average compared with 29.5 days (p = 0.001) for those who received standard therapy.
Dopexamine is a beta2 adrenoceptor and dopamine receptor agonist, which is approved in Europe in indications related to heart failure. Dopexamine is not approved for use currently in the US, Canada or Japan.
"ToleroCare has great potential to dramatically improve patients' recovery following major surgery, as well as to significantly reduce costs by shortening the time spent in hospital. With approximately 825,000 high-risk surgical procedures carried out each year in the US, and the high cost associated with hospital stays, ToleroCare is targeting a major market opportunity," said Steve Harris, Circassia's CEO. "Dopexamine provides Circassia with a further phase II clinical-stage development programme that fits well with our outsourced business model. By establishing a commercial-scale supply chain for dopexamine, we are well positioned to rapidly progress ToleroCare to market."
Circassia is a specialty biopharmaceutical company focused on the fields of allergy and critical care. The company has a highly experienced management team with a proven track record in product development and commercialization, and having successfully completed two fundraising rounds is backed by a syndicate of world-class venture capital and institutional investors, which includes Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.
Circassia's lead products target allergies utilizing the company's
proprietary T-cell epitope desensitization technology, ToleroMune(R). The
company is also developing its ToleroTrans(R) organ anti-rejection
technology, which uses a similar approach to down-regulate immune responses
in transplant patients. Circassia has a number of ongoing development
programmes, with the most advanced against cat-dander allergy in phase II
For more information please visit http://www.circassia.co.uk.
Steve Harris Rob Budge
CEO RJB Communications
Circassia Tel: +44(0)1865-760969
Tel: +44(0)1865-784574 Mobile: +44(0)7710-741241
|SOURCE Circassia Ltd|
Copyright©2008 PR Newswire.
All rights reserved